Akebia Therapeutics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
167
- Stock Symbol
-
AKBA
- Investments
-
3
- Share Price
-
$1.46
- (As of Friday Closing)
Akebia Therapeutics General Information
Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Contact Information
Website
www.akebia.comCorporate Office
- 245 First Street
- Suite 1400
- Cambridge, MA 02142
- United States
Corporate Office
- 245 First Street
- Suite 1400
- Cambridge, MA 02142
- United States
Akebia Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.46 | $1.44 | $0.78 - $2.48 | $307M | 210M | 2.78M | -$0.21 |
Akebia Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 214,679 | 244,775 | 62,275 | 311,417 |
| Revenue | 174,497 | 194,623 | 292,484 | 211,650 |
| EBITDA | 4,629 | (8,266) | (40,842) | (224,118) |
| Net Income | (40,442) | (51,925) | (94,226) | (282,024) |
| Total Assets | 220,196 | 241,703 | 356,054 | 529,347 |
| Total Debt | 49,509 | 48,121 | 99,783 | 136,048 |
Akebia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Akebia Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Akebia Therapeutics Comparisons
Industry
Financing
Details
000000
000000
Akebia Therapeutics Competitors (82)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Travere Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
| Genentech | Formerly VC-backed | South San Francisco, CA | 00000 | 00.000 | 00000000000 | 00.000 |
| Lineage Cell Therapeutics | Corporation | Carlsbad, CA | 00 | 00000 | 000000000 | 00000 |
| SanBio | Formerly VC-backed | Tokyo, Japan | 00 | 000.00 | 000000000 | 000.00 |
Akebia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Akebia Therapeutics Patents
Akebia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230144457-A1 | Methods for treating viral infections, organ injury, and related conditions | Pending | 27-Oct-2021 | 00000000000 | 0 |
| EP-4301352-A1 | Modulation of drug-drug interactions of vadadustat | Pending | 01-Mar-2021 | 00000000000 | |
| AU-2022229275-A1 | Modulation of drug-drug interactions of vadadustat | Pending | 01-Mar-2021 | 00000000000 | |
| JP-2024510926-A | Modulation of vadadustat drug-drug interactions | Pending | 01-Mar-2021 | 00000000000 | |
| US-20240148707-A1 | Modulation of drug-drug interactions of vadadustat | Pending | 01-Mar-2021 | A61K31/44 |
Akebia Therapeutics Executive Team (27)
| Name | Title | Board Seat |
|---|---|---|
| John Butler | President, Chief Executive Officer & Board Member | |
| Richard Malabre | Chief Accounting Officer, Accounting | |
| Nicholas Grund | Chief Commercial Officer | |
| Michael Pape Ph.D | Co-Founder | |
| Steven Burke MD | Chief Medical Officer & Senior Vice President |
Akebia Therapeutics Board Members (27)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adrian Adams | Self | Chairman & Board Member | 000 0000 |
| Cynthia Smith | Self | Board Member | 000 0000 |
| John Butler | Akebia Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 |
| LeAnne Zumwalt | Self | Board Member | 000 0000 |
| Michael Rogers | Self | Board Member | 000 0000 |
Akebia Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Akebia Therapeutics Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cyclerion Therapeutics (Rights to Develop and Commercialize Praliciguat) | 04-Jun-2021 | 000000000 | 000 | Buildings and Property | 0000 0000 |
| Keryx Biopharmaceuticals | 13-Dec-2018 | 0000000000 | 00.00 | Pharmaceuticals | 0000 0000 |
| Janssen Pharmaceutica (hypoxia-inducible factor) | 13-Feb-2017 | Corporate Asset Purchase | 00000 | Buildings and Property | 0000 0000 |
Akebia Therapeutics ESG
Risk Overview
Risk Rating
Updated August, 27, 2022
26.99 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile
Biotechnology
Subindustry
00 of 465
Rank
Percentile
Akebia Therapeutics FAQs
-
When was Akebia Therapeutics founded?
Akebia Therapeutics was founded in 2007.
-
Who is the founder of Akebia Therapeutics?
Michael Pape Ph.D, Joseph Gardner Ph.D, Joshua Fairbank, and Robert Shalwitz MD are the founders of Akebia Therapeutics.
-
Who is the CEO of Akebia Therapeutics?
John Butler is the CEO of Akebia Therapeutics.
-
Where is Akebia Therapeutics headquartered?
Akebia Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Akebia Therapeutics?
Akebia Therapeutics has 167 total employees.
-
What industry is Akebia Therapeutics in?
Akebia Therapeutics’s primary industry is Biotechnology.
-
Is Akebia Therapeutics a private or public company?
Akebia Therapeutics is a Public company.
-
What is Akebia Therapeutics’s stock symbol?
The ticker symbol for Akebia Therapeutics is AKBA.
-
What is the current stock price of Akebia Therapeutics?
As of 13-Sep-2024 the stock price of Akebia Therapeutics is $1.46.
-
What is the current market cap of Akebia Therapeutics?
The current market capitalization of Akebia Therapeutics is $307M.
-
What is Akebia Therapeutics’s current revenue?
The trailing twelve month revenue for Akebia Therapeutics is $174M.
-
Who are Akebia Therapeutics’s competitors?
Travere Therapeutics, Alnylam Pharmaceuticals, Genentech, Lineage Cell Therapeutics, and SanBio are some of the 82 competitors of Akebia Therapeutics.
-
What is Akebia Therapeutics’s annual earnings per share (EPS)?
Akebia Therapeutics’s EPS for 12 months was -$0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
